Compare Charles River Laboratories Intl. Inc (CRL) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Msci Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Msci Inc trades at $565.12 (market cap $40.38B). The key difference: Msci Inc is far larger — about 2.8× Charles River Laboratories Intl. Inc's market cap, and Msci Inc pays a 1.48% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Msci Inc for 82 Days on average.
| CRL | MSCI | |
|---|---|---|
Market Cap | $14.23B | $40.38B |
Volume | 1,176,885 | 414,140 |
Sector | Health | Financials |
52-Week High | $310.77 | $643.83 |
52-Week Low | $149.93 | $511.84 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $17.06B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
MSCI trades at $561.67, up 1.13% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $3.13B in 2025, with a high net income margin of 40.73%. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow from operations. Analyst consensus is strongly positive, with a $701.71 price target, supported by 74% buy ratings. Key developments include the completed acquisition of First Street, enhancing its climate risk analytics offerings.
The outlook for MSCI is favorable, driven by recurring revenue streams, high client retention, and growth in passive investing and private markets. Risks include high valuation multiples, significant long-term debt of $4.51B, and sensitivity to financial market cycles. The stock presents a long-term growth opportunity, but investors should monitor execution on earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
